Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to confirm the feasibility of using a panel of endogenous
substrates/metabolites as a robust biomarker of OCTs and OATs by conducting a controlled,
comprehensive clinical drug-drug interaction study in healthy adult volunteers. Metformin and
furosemide will be used as probe drugs for OCTs and OATs, respectively; cimetidine and
probenecid will be used as corresponding inhibitors. Results from this study will validate
this novel approach, which will be extended to children by collaborators at Children's Mercy
Hospital in Kansas City, MO.
Phase:
Early Phase 1
Details
Lead Sponsor:
Washington State University
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Institutes of Health (NIH)